Trevi Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Trevi Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New Haven
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TRVI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001563880
- EIN
- 45-0834299
Board of directors
-
Anne Vanlent · DirectorSince 2023
-
David P. Meeker · DirectorSince 2023
-
Dominick Colangelo · DirectorSince 2023
- Since 2023
-
James Cassella V · DirectorSince 2023
-
Jennifer L. Good · Director · President & CEOSince 2023
- Since 2023
Chief executives
Jennifer L. Good
· President & CEO
Dates unknown
Director election results
Annual meeting of June 11, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.5%
-
99.7%
Board connections
5 of this board's directors also sit on 11 other boards.
- via David P. Meeker, Edward T. Mathers and Jennifer L. Good
- via Michael Thomas Heffernan
- via Michael Thomas Heffernan
- via Michael Thomas Heffernan
- via David P. Meeker
- via Edward T. Mathers
- via Edward T. Mathers
- via David P. Meeker
- via Edward T. Mathers
- via Dominick Colangelo
- via Michael Thomas Heffernan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $595,806
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Michael Thomas Heffernan Director | Option exercise | +18,421 | $3.04 | $56,000 |
| Sep 15, 2026 | Michael Thomas Heffernan Director | Open-market sale | −18,321 | $15.09 | $276,464 |
| Sep 15, 2026 | Michael Thomas Heffernan Director | Open-market sale | −100 | $15.88 | $1,588 |
| Sep 15, 2026 | Michael Thomas Heffernan Director | Option exercise | +21,052 | $3.33 | $70,103 |
| Sep 15, 2026 | Michael Thomas Heffernan Director | Open-market sale | −20,952 | $15.09 | $316,166 |
| Sep 15, 2026 | Michael Thomas Heffernan Director | Open-market sale | −100 | $15.88 | $1,588 |
| Dec 2, 2025 | Galletta Christopher Officer (See Remarks) | Option exercise | +4,225 | $0.51 | $2,155 |
| Apr 17, 2025 | Scott D. Sandell 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | Ali Behbahani 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | NEA Partners 16, L.P. 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | Florence Anthony A. Jr. 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | BASKETT FOREST 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | Makhzoumi Mohamad 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | Walker Paul Edward 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
| Apr 17, 2025 | Carmen Chang 10% owner | In-the-money exercise | +1,851,852 | $1.37 | $2,537,037 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.